Vollebregt, Madelon A. http://orcid.org/0000-0002-1347-7073
Kenemans, J. Leon
Buitelaar, Jan K.
Deboer, Tom
Cain, Sean W.
Palmer, Donna
Elliott, Glen R.
Gordon, Evian
Fallahpour, Kamran
Arns, Martijn
Article History
Received: 12 June 2019
Accepted: 28 October 2019
First Online: 20 November 2019
Compliance with ethical standards
:
: MA reports research grants and options from Brain Resource (Sydney, Australia) and shares from neuroCare Group (Munich, Germany); DP has received income and stock options with the role of science and data processing manager as an employee with Brain Resource Ltd.; EG is founder and receives income as Chief Executive Officer and Chairman for Brain Resource Ltd. He has stock options in Brain Resource Ltd. JKB has been a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, and Servier in the past years. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. MV, LK, TD, and GE report no financial disclosures.
: The study complies with the principles of the “Declaration of Helsinki 2008,” the International Conference on Harmonization (ICH) guidelines, and the laws and regulations of the country in which the research is conducted, including the principles of “Good Clinical Practice” as outlined in the U.S. Code of Federal Regulations. All sites received approval from their Institutional Review Board (IRB)/Independent Ethics Committee (IEC) prior to participant enrollment and each participant (and/or guardian) provided their informed consent to be involved in the study.